Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of malignant clonal disorders of hematopoietic stem cells (HSC), characterized by reduced peripheral blood cell counts (cytopenias) with dysplasia in one or more cell lineages and increased risk of progression to acute myeloid leukemia (AML) 1 . Apoptosis is a prominent feature of the World Health Organization (WHO) low-intermediate risk subgroups of MDS, although whether apoptosis is directly responsible for the cytopenias remains unproven. Mammals possess two major apoptotic pathways, the death receptor pathway and the BCL2-regulated (also called stress, mitochondrial or intrinsic) pathway 2 . Increased apoptosis in MDS has been attributed to activation of the death receptor pathway 3 , although recent studies of a mouse model of the WHO del(5q) subtype have implicated the BCL2-regulated pathway through activation of TP53 4 .
As in other cancers 5, 6 , oncogene-induced apoptosis in MDS may function as a protective mechanism by reducing the pool of pre-malignant cells that can acquire additional genetic or epigenetic changes required for progression to AML. As such, overcoming apoptosis may be an important mechanism of malignant transformation to AML 6 . Consistent with this notion, more aggressive, high risk subgroups of MDS have an increased expression of anti-apoptotic BCL2-related proteins relative to pro-apoptotic BH3-only proteins 7 .
One of the major hurdles of studying MDS is the genetic and cellular heterogeneity of human MDS and the inability to grow primary samples in vitro or in immune-deficient mouse strains. To this end, we have generated a transgenic mouse model of MDS by hematopoieticexpression of the fusion gene Nup98-HoxD13 (NHD13) of the t(2;11)(q31;p15) chromosomal translocation 8 . The NHD13 model recapitulates many of the features of human MDS, with an early pre-leukemic phase of cytopenias and increased apoptosis in the bone marrow followed by only.
For personal use at University of Melbourne Library on September 4, 2012. bloodjournal.hematologylibrary.org From the development of AML harboring mutations in genes such as N-Ras 9 . Here, we have used this MDS model to investigate the role of apoptosis in cytopenias and leukemic transformation.
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Materials and Methods
Mice. The NHD13 mice have been described previously 8 . only.
For personal use at University of Melbourne Library on September 4, 2012. bloodjournal.hematologylibrary.org From Gene Expression Analysis. Microarray analyses were performed using the Illumina iScan microarray platform (San Diego, CA). Briefly, total RNA was isolated from FACS-sorted LK cells from the pooled BM from three mice of each genotype by using the Trizol method and reverse transcribed using a T7-promoter-oligo(dT) primer. An in vitro transcription reaction with biotin labeled nucleotides (Ambion labeling protocol) was then performed, and the labeled cRNA samples were hybridized to the Illumina Mouse WG-6 v2.0 beadchip (45,281 transcripts), washed and scanned on the Illumina iScan. The resulting image files were analyzed using Illumina Beadstudio software to generate quantitative expression scores with mean standard deviation and statistical evaluation of detection reliability averaged across the 30-50 built-in technical replicates for each transcript. Differences in gene expression levels between NHD13 mice and WT mice were determined by using three replicates from each group. The data analysis software package GeneSpring v11.5.1 was used to detect fold-change differences of >2 with a statistical significance of p<0.05 using the Student t-test on Log transformed data. All microarray data are available on the Gene Expression Omnibus (GEO) database under accession number
GSE39692.
Quantitative RT-PCR. Total RNA was prepared from FACS-sorted LK cells by using the Trizol (Invitrogen, Carlsbad, CA) reagent according to the manufacturer's instructions. cDNA was transcribed from 1 g of RNA using the Roche Transcriptor kit according to the manufacturer's instructions. Expression of Cdkn1a mRNA was quantified using the primer pair: sense 5'-ggtgggcccggaacatct-3', anti-sense 5'-gggccctaccgtcctactaat-3'. Expression of BCL2 mRNA was quantified using the primer pair: sense 5'-gtacctgaaccggcatctg-3', anti-sense 5'-ggggccatatagttccacaa-3'. Expression of Hoxc6 mRNA was quantified using the primer pair: sense Statistics. Student's t test was used to determine significance of data, with the exception of animal survival studies for which we used the Mantel-Cox log rank test. All error bars represent the standard error of the mean (SEM).
Results
Increased apoptosis and proliferation of pre-malignant progenitor cells. To characterize the apoptotic phenotype in early MDS, we analyzed NHD13 mice at 3 months of age, when the animals displayed macrocytic anemia (reduced hematocrit and elevated red cell mean cell volume; MCV) and thrombocytopenia despite normal neutrophil counts (Fig. 1A) . 
Apoptosis is not due to activation of the death receptor pathway. Excessive apoptosis in
MDS has been attributed to activation of the death receptor pathway within an abnormal bone marrow microenvironment 15 . To assess the role of the death receptor pathway in the apoptosis of NHD13 hematopoiesis, we crossed NHD13 mice with mice deficient in tumor necrosis factor (Tnf -/-) 10 pathway was unlikely to be an important mechanism of apoptosis in NHD13 hematopoiesis.
BCL2 prevents apoptosis and restores blood counts.
We compared the gene expression profile of LK cells isolated from three-month-old NHD13 and wild-type mice to identify factors that might explain the increased apoptosis in NHD13 hematopoiesis (Table S1 ). The most dramatic changes were increased expression of a number of homeobox genes (Hoxc6, Hoxb7, Hoxa9 and Pbx3), many of which have been implicated in MDS and AML 17 . Analysis of genes regulating apoptosis revealed no abnormal expression of components of the death receptor pathway, consistent with our earlier findings (Fig. 2) . The major apoptosis-related abnormality was a 3.6-fold reduction in Bcl2 (Table S1 ). Q-RT-PCR confirmed reduced expression of Bcl2 in LK cells ( Fig 3A) . Reduced expression of BCL2 protein in NHD13 LK cells was confirmed by flow cytometry (Fig. 3B ). Expression analysis of BCL2-related genes using a published array dataset of CD34 + purified MDS bone marrow cells 18 revealed a significant reduction in BCL2 in the del(5q) subset ( Figure S3 ), where apoptosis has been linked to activation of the intrinsic pathway 4 .
Increased expression of the pro-apoptotic genes BID and PUMA and the anti-apoptotic gene only.
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The relative expression of the anti-apoptotic BCL2-related proteins is increased in higher risk human MDS 19 . Similarly, Bcl2 expression was higher in AML cells arising in NHD13 mice (Fig 3A) . Therefore, the NHD13 mouse model of MDS parallels the temporal changes in BCL2-related proteins seen in human MDS.
To evaluate the impact of reduced expression of BCL2 in early MDS, NHD13 mice were crossed with BCL2 transgenic mice, which express human BCL2 in all hematopoietic cells 12 .
Using Q-RT-PCR primers that amplify both mouse and human BCL2 mRNA, we found that levels of BCL2 in LK cells from NHD13/BCL2 mice were increased 10-fold compared to wildtype LK cells (Fig. S4 ). Enforced BCL2 expression inhibited apoptosis of LKS cells (Fig. 4A) , which restored the numbers of LKS cells to levels comparable with BCL2 littermate controls (Fig.   4B ). Reduced apoptosis and increased numbers of LKS in H2K-BCL2 transgenic mice has been previously reported 20 . In addition to rescue of cell survival and cell numbers, BCL2 overexpression restored the in vitro growth of myeloid and erythroid NHD13 progenitors (Fig. 4C ).
Apoptosis is a postulated mechanism of cytopenias in MDS although there is little direct evidence to support this hypothesis 21 . In the NHD13 mice, blocking apoptosis corrected the macrocytic anemia of three-month old mice (Fig. 4D) . Platelet numbers were not restored to wild-type levels, although they were comparable to the platelet numbers observed in the BCL2 mice ( Fig. 4D) , which are known to be thrombocytopenic 12 . Thus, apoptosis was an important mechanism of cytopenia in this model. 2D ), it seemed unlikely that BCL2 was inhibiting apoptosis through the death receptor pathway.
Overexpression of BCL2 prevents leukemic transformation. 5A) . In contrast and contrary to expectation, none of the 27 NHD13/BCL2 mice developed AML within this time frame despite abnormal expression of the homeobox genes to levels greater than NHD13 alone (Fig. 5B) . The absence of AML in NHD13/BCL2 mice was not attribution to early deaths from T-cell acute lymphoblastic leukemia (T-ALL), which developed in NHD13 mice at a similar frequency and onset (Fig. 5C ). Follicular-like B-cell lymphomas were the predominant cause of death in BCL2 mice as previously described 30 . Consequently, the difference in overall survival between NHD13/BCL2 and NHD13 mice was explained by the prevention of AML (Fig. 5D) . Thus, apoptosis is required for transformation of pre-malignant cells in this disease model. For
BH3-only protein PUMA (essential for DNA damage-induced, p53-mediated apoptosis) abrogated compensatory proliferation and replication stress-associated DNA damage of BM-derived LKS cells, the cell of origin of thymic lymphoma. To determine whether a similar mechanism underpinned the prevention of AML from pre-malignant NHD13 progenitors, we examined the cell cycle of the LKS population in NHD13/BCL2 mice (Fig. 6A) . Expression of the BCL2 transgene alone had no significant effect on cell quiescence, but BCL2 over-expression in NHD13 LKS cells corrected the cell cycle defect seen in NHD13 progenitors.
To explore the cell cycle changes, we examined expression of the major cell cycle regulators: Cdkn1a (p21) and Cdkn1b (p27). The reduced quiescence of pre-malignant NHD13 progenitors correlated with reduced expression of p21 (Fig. 6B ) with no detectable change in p27 (Fig. S6) . Thus, the restoration of cell quiescence may be explained by increased p21 expression in NHD13/BCL2 pre-malignant cells.
Replicative stress induced by oncogenes leads to the formation of DNA double-strand breaks (DSBs) 5 . H2AX is a variant H2A histone protein, which becomes phosphorylated (γH2AX) when associated with DSBs, and can thereby be used as a marker of DSB occurrence.
Consistent with oncogene-induced DNA damage, NHD13 progenitor cells had increased γ H2AX as measured by a flow-based assay that enabled exclusion of apoptotic cells by co-staining for activated caspase-3 ( Fig. 6C and S7 ). Co-expression of the BCL2 transgene reduced γ H2AX levels to wild-type levels, although they remained higher than BCL2 transgenic cells. Overall, these results demonstrate that BCL2 expression in pre-malignant progenitors restores cell cycle quiescence and reduces the formation of DSBs.
For (Fig. 7) . Increased apoptosis may also explain the increased proliferation observed in human MDS 14 . It is not clear how apoptosis drives proliferation in the setting of oncogenic stress but one possibility is the release of mitogens such as Wnt3a and prostaglandin E2 by apoptotic cells, which is important for tissue regeneration 37 . Alternatively, BCL2 may directly slow cell cycle re-entry from G 0 38 , although no such effect was seen in BCL2 mice (Fig.   6A ). Collectively, we propose that inhibition of apoptosis by BCL2 reduces replicative stress and DNA damage in pre-malignant cells, which reduces genomic instability, an important mechanism of acquiring additional genetic mutations for cancer progression (Fig. 7) .
Several caveats of this work should be recognized. These results raise a practical concern that inducing apoptosis by chemotherapy may be counterproductive, particularly in pre-malignant diseases such as low risk MDS. Although we have not directly addressed this possibility, a recent report has shown that radiation-induced killing can promote tumor regrowth by a caspase dependent mechanism 39 . Finally, our findings raise the possibility that inhibitors of apoptosis may be useful for improving cytopenias and delaying leukemic progression in low risk MDS. 
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